<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04264988</url>
  </required_header>
  <id_info>
    <org_study_id>2018-6/17</org_study_id>
    <nct_id>NCT04264988</nct_id>
  </id_info>
  <brief_title>Major Pelvic Hemorrhage in Complex Surgery</brief_title>
  <official_title>Management and Outcomes of Major Pelvic Hemorrhage in Patients Undergoing Complex Abdomino-Pelvic Surgery: A Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acibadem University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bursa Medicana Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dokuz Eylul University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cukurova University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pamukkale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ankara University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TOBB University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gazi University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baskent University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ege University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medipol University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gulhane Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Acibadem University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemorrhage is a challenging complication of pelvic surgery. In this study, the investigators&#xD;
      aimed to analyze the causes, management, and outcomes of major pelvic hemorrhage in patients&#xD;
      undergoing complex abdomino-pelvic surgery. Participants who had a major intraoperative&#xD;
      pelvic hemorrhage during complex abdomino-pelvic surgery at 11 tertiary referral centers were&#xD;
      included. Participant characteristics, causes of hemorrhage, management strategies, and&#xD;
      outcomes including morbidity and mortality analyses were evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 19, 2018</start_date>
  <completion_date type="Actual">October 19, 2018</completion_date>
  <primary_completion_date type="Actual">October 19, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Peri-operative outcomes</measure>
    <time_frame>Within postoperative day 30</time_frame>
    <description>Complication rate (Number of participants who had a complication divided by total number of participants)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Pelvic Bleeding</condition>
  <arm_group>
    <arm_group_label>Patients who had pelvic hemorrhage</arm_group_label>
    <description>Patients who had pelvic hemorrhage during complex abdomino-pelvic surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stopping of pelvic bleeding via several surgical methods</intervention_name>
    <description>Those surgical methods were pelvic packing, electrocautery, energy devices, suturing, fastener, muscle welding, procoagulant chemicals, and combination of those</description>
    <arm_group_label>Patients who had pelvic hemorrhage</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient operated for complex abdominopelvic surgery including radical oncologic operations&#xD;
        for the primary advanced or recurrent carcinoma of pelvic organs, pelvic cytoreduction,&#xD;
        revisional/redo operations for failed ileal/colonic pouches, repair of the entero-enteral,&#xD;
        entero-cutaneous, entero-vesical and entero-vaginal fistulas who had presacral bleeding in&#xD;
        centers which had over 225 colorectal cases per year were included. Major pelvic bleeding&#xD;
        is defined as symptomatic bleeding originating from pelvis, bleeding leading to transfusion&#xD;
        of ≥2 units of whole blood or packed red cells; surgical site bleeding that requires a&#xD;
        second intervention; or surgical site bleeding that is unexpected and prolonged and/or&#xD;
        sufficiently large to cause hemodynamic instability with an associated decrease in&#xD;
        hemoglobin ≥20 g/L.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who had major pelvic bleeding during complex abdominopelvic surgery&#xD;
&#xD;
          -  Patients operated in hospitals where over 225 colorectal cases were performed every&#xD;
             year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients operated for palliative intent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Acibadem Maslak Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34457</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tin Fluorides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

